584 results about "Pancreatic structure" patented technology

Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.

Apparatus (18) is provided for sensing electrical activity of a pancreas (20) of a patient. The apparatus (18) includes a set of one or more electrodes (100), adapted to be coupled to the pancreas (20), and to generate activity signals indicative of electrical activity of pancreatic cells which are in a plurality of islets of the pancreas (20). The apparatus (18) also includes a control unit (90), adapted to receive the activity signals, and to generate an output signal responsive thereto.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

A method of glucose level control, comprising providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased.

Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.

A pancreatic controller, comprising:at least one electrode adapted for electrifying at least a portion of a pancreas; anda controller programmed to electrify said electrode so as to positively control at least the effect of at least two members of a group consisting of blood glucose level, blood insulin level and blood level of another pancreatic hormone. In one example, the controller controls insulin, glucagon and / or glucose blood levels.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

A method of glucose level control comprising, providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased compared to a regular insulin response in a same person.

The present invention uses peripheral blood monocyte-lymphocyte for the early diagnosis of pancreatic cancer, as well as other conditions of the pancreas and other organs. The peripheral blood lymphocytes recognize the new neoplasm in the pancreas, as well as disease processes in other organ systems. The evaluation of this specific recognition of the disease process by the peripheral blood monocyte-lymphocyte through gene microarray expression patterns constitute a successful method for the early detection of pancreatic cancer and other organ disease processes. This document describes the process used in this method of early diagnosis.

A product for implantation within a soft tissue site of the human or animal body comprises a pulverized or morselized matrix of a substantially non-mineralized native soft tissue (NSTM) of the human or animal body, provided in a therapeutic amount to induce growth of native tissue or organs and healing at the tissue site. The NSTM is composed of at least one soft tissue selected from the group consisting of cartilage, meniscus, intervertebral disc, ligament, tendon, muscle, fascia, periosteum, pericardium, perichondrium, skin, nerve, blood vessels, and heart valves or from organs such as bladder, lung, kidney, liver, pancreas, thyroid, or thymus. Preferably, the NSTM is composed of a soft tissue of the same type of tissue native to the repair site. In another embodiment, the NSTM includes soft tissue of a different type than the tissue repair site.

The invention relates to a Chinese medicinal preparation for treating the diabetes, which is prepared from 47 raw material medicaments in part by weight: astragalus, siberian solomonseal rhizome, common yam rhizome, cornus fruit and the like. A preparation method 1 for the Chinese medicinal preparation comprises the following steps: (1) preparing aqueous extract of the raw material medicaments; (2) preparing oral liquid from the aqueous extract; (3) drying and crashing the aqueous extract obtained by the step (1), and passing the powders through a screen to prepare medicament extract powders; and (4) preparing tablets, granules, pills, soluble granules or capsules with the medicament extraction powders. A preparation method 2 for the Chinese medicinal preparation comprises the following steps: (1) drying fresh pig pancreas and grinding the fresh pig pancreas into powders; (2) crushing other raw material medicaments, passing the powder through a screen to prepare medicament powders; (3) uniformly mixing the pig pancreas powders and the medicament powders, disinfecting and sterilizing to obtain raw powders; and (4) preparing oral tablets, granules, pills, soluble granules or capsules with the raw powders. Based on the principle of monarch, subject, assistant and envoy, the medicament of the invention has synergistic effect, addresses both the symptoms and root causes, has better curative effect on the diabetes, and has obvious effect of treating serious diabetes. The raw medicinal materials adopted by the Chinese medicinal preparation are common Chinese medicaments, have low production cost and have no toxic or side effects basically.

An implant device comprising an electrode for electrical stimulation of the pancreas, the device being adapted to be inserted into the pancreas, and to change at least one of its properties after being inserted into the pancreas, so that it will cause less irritation to the pancreas than before changing said property.

Method and system for organ preservation. According to one aspect, an organ may be preserved by being perfused with an in situ generated preserving gas. The organ may be, for example, a human or porcine pancreas, and perfusion of the pancreas may be anterograde, retrograde, ductal, anterograde / ductal, or retrograde / ductal. The preserving gas used to perfuse the organ may be dissolved in a liquid and then administered to the organ as a gas / liquid solution or may be mixed with one or more other gases and then administered to the organ as a gas / gas mixture. The preserving gas may be, for example, oxygen gas generated in situ using an electrochemical oxygen concentrator. According to another aspect, an organ preservation system may include an electrochemical oxygen concentrator having a water vapor feed, as well as auxiliary equipment to control and measure delivery pressure, flow, temperature and humidity.

The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented.

Laser tissue welding can be achieved using tunable Cr4+ lasers, semiconductor lasers and fiber lasers, where the weld strength follows the absorption spectrum of water. The use of gelatin and esterified gelatin as solders in conjunction with laser inducted tissue welding impart much stronger tensile and torque strengths than albumin solders. Selected NIR wavelength from the above lasers can improve welding and avoid thermal injury to tissue when used alone or with gelatin and esterified gelatin solders. These discoveries can be used to enhance laser tissue welding of tissues such as skin, mucous, bone, blood vessel, nerve, brain, liver, pancreas, spleen, kidney, lung, bronchus, respiratory track, urinary tract, gastrointestinal tract, or gynecologic tract and as a sealant for pulmonary air leaks and fistulas such as intestinal, rectal and urinary fistulas.

A method for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, glands, and muscles in a patient's body. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body. The harvested stem cells are then intraluminally applied through a designated natural body vessel. During the time the stem cells are being applied to the targeted tissue downstream, the designated vessel or duct is selectively occluded to increase concentration and pressure of the applied adult stem cells by the vessel.

The invention provides a composition for protecting islet cells during isolation and transplantation, as well as a method for increasing survival of islets and islet cells during harvest from the donor pancreas, isolation and culture, transportation, and transplantation into the recipient. The composition provides at least one Vitamin E homolog that, when combined with cell culture media, increases islet cell survival.

Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. The formulation may be dispersed in a suture or adhesive for administration at the time of or as released following suturing or gluing of a wound, thereby limiting bleeding, loss of tissue fluids, or other fluids such as those produced by parenchymal tissues such as the liver, pancreas, and gastrointestinal tract. The formulation may be applied to any site of bleeding, in a bandage, gauze, sponge, or other material, for immediate control of bleeding, or released later to control bleeding if the initial treatment such as suturing or pressure is insufficient. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate. In another embodiment, the formulation is provided as a coating on a device, for example a stent or a catheter. The material is also useful to isolate tissue, for preservation of tissue for subsequent transplantation or reattachment, and as a bulking, stabilizing or hydrating agent.

A method of preparing and using a sterile non-toxic pyrogen-free cold extract from the leaves of Nerium oleander as a supplementary medication to cancer chemo-, hormon and / or radiotherapy to restore and / or ameliorate the immune system of the patient and / or to decrease side effects and increase the antitumor effects of radiotherapy and chemotherapeutics, particularly when used in combination with taxol, adriamycin, cisplatin, 5-fluoro-uracil, alimta, cyclophosphamide, mitomycin-C, navelbine, taxotere and topotecan, respectively, and its use in the manufacture of a medicament for the treatment of one or more cancers of bladder, kidney, liver, ovary, pancreas, testicle, uterus, and vagina as well as pleuramesotheliomas and Hodgkin's lymphomas.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and / or prostate cancer.

The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT1B or 5HT1D receptor agonist, (e.g., a triptan). These methods can be used, for example, to treat a human suffering from visceral pain secondary to an underlying disease of a visceral organ, such as pancreatitis. Visceral pain treatable by the methods of the invention may also be secondary to a disease of the liver, kidney, ovary, uterus, bladder, bowel, stomach, esophagus, duodenum, intestine, colon, spleen, pancreas, appendix, heart, or peritoneum.

A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells.

The present invention proposes formative agent of protein complex, in which a polyphenol is useful component, and the agent is useful as gene complex, cell adhesion inhibitor or immune tolerogen. The polyphenol of forming the agent is selected from catechin group consisting of epigallocatechin-gallate, tannic acids, or proanto-dianisidine, a protein of the protein complex is selected from proteins consisting of animal proteins composed of polypeptide chain of peptide-combined amino acids, vegetative proteins, nucleus proteins, glycogen proteins, lipo-proteins and metal proteins, the gene complex comprises by compositing genes by polyphenol catechins in order to introduce genes to cells of animals or human bodies, a cell composed of the cell adhesion inhibitor is selected from cells consisting of an animal cell including a stem cell, skin cell, mucosa cell, hepatocyte, islet cell, neural cell, cartilage cell, endothelial cell, epidermal cell, osteocyte or muscle cell isolated from human or animal organism, or sperm, ovum or fertilized egg of domestic animals or fishes and a tissue or an organ for transplantation of the immune tolerogen is selected from the tissue or the organ consisting of skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, bowels, nerve, lung, placenta or pancreas.

The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder, bones, brain, breast, cervix, colon, colorectum, esophagus, gastrointestinal tract, heart, kidney, liver, large intestine, lungs, mouth, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, skin, small intestine, spleen, stomach, thymus, thyroid, testicles, urinary tract, uterus, vagina, and so forth.

This invention relates to inhibition of αv integrins, especially αvβ3 and αvβ6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells / myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis / cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.

A method is described for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, and glands in a patient's body. In the method, stem cells that have the capability to repair tissue of the selected organ are intraluminally applied through a designated natural body vessel or duct leading to a predetermined target site of the tissue of the selected organ to be repaired. The stem cells are delivered into the respective vessel or duct through a catheter having a proximal portion of relatively larger central lumen diameter and outer diameter, and a distal portion of relatively smaller central lumen diameter and outer diameter, the two portions being integral with one another so that stem cells delivered into the central lumen of the proximal portion will flow through and exit the central lumen of the distal portion, the lumen diameter and length of each of the two portions being selected to minimize the pressure drop across the catheter during flow of the stem cells.

The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.

A perfusion system is so formed that enclosed areas may be formed in the artery system related to the pancreas and the venous system related to the pancreas, respectively, by using balloon catheters, the blood inside the venous system in the enclosed area may be extracted outside the human body, and that, after injecting a pharmaceutical such as anticancer agent into the extracted blood, the extracted blood including pharmaceutical may be returned to the artery system in the enclosed area again.